nach oben

Erschienen in:

05.01.2022 | Original Article

Nutritional status alterations after chimeric antigen receptor T cell therapy in patients with hematological malignancies: a retrospective study

verfasst von: Shuyi Ding, Lingxia Cai, Aiyun Jin, Xiaoyu Zhou, Jiali Yan, Linqin Wang, Houli Zhao, Tingting Wang, Yongxian Hu

Erschienen in: Supportive Care in Cancer | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The influence of innovative chimeric antigen receptor T cell (CAR-T) therapy for hematological malignancies on nutritional status remains unknown. Therefore, we aim to explore the alterations of nutritional status after CAR-T cell therapy in patients with hematological malignancies.

Methods

We retrospectively collected the data of patients with acute leukemia (AL), lymphoma, and multiple myeloma (MM), who underwent CAR-T therapy at our hospital from 2018 to 2020. The serum albumin, triglyceride, and cholesterol before and 7, 14, and 21 days after CAR-T cell infusion were compared and analyzed.

Result

A total of 117 patients were enrolled, consisting of 39 AL, 23 lymphoma, and 55 MM patients. The baseline albumin, triglyceride, and cholesterol were 37.43 ± 5.08 mg/L, 1.63 ± 0.74 mmol/L, and 3.62 ± 1.03 mmol/L, respectively. The lowest albumin level was found at 7 days after CAR-T cell infusion compared with baseline (P < 0.001), while the levels of triglyceride increased at 14 and 21 days (P < 0.001, P = 0.036). The levels of cholesterol at 7, 14, and 21 days after CAR-T cell infusion were lower than baseline (all P < 0.05). Spearman’s correlation coefficient showed cytokine release syndrome grade was negatively correlated with the levels of albumin at 7 days and cholesterol at 21 days after CAR-T cell infusion (r = − 0.353, P < 0.001; r = − 0.395, P = 0.002).

Conclusion

The alterations of different nutrition-related biochemical parameters varied after CAR-T cell therapy. The levels of albumin and total cholesterol after CAR-T cell infusion were negatively correlated with the grade of cytokine release syndrome. Specific screening and intervention for malnutrition in patients receiving CAR-T cell therapy need to be explored in further studies.

Mullard A (2017) FDA approves first CAR T therapy. Nature Reviews Drug Discovery 16(10):669–669. https://doi.org/10.1038/nrd.2017.196CrossRefPubMed

Mullard A (2017) Second anticancer CAR T therapy receives FDA approval. Nature Reviews Drug Discovery 16(12):818–818. https://doi.org/10.1038/nrd.2017.249CrossRefPubMed

Ma S et al (2019) Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci 15(12):2548–2560CrossRef

Lin WY et al (2020) Gene modified CAR-T cellular therapy for hematologic malignancies. Int J Mol Sci 21(22):8655CrossRef

Park JH et al (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378(5):449–459CrossRef

Brudno JN, Kochenderfer JN (2019) Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev 34:45–55CrossRef

Neelapu SS et al (2018) Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47–62CrossRef

Skorka K et al (2020) The application of CAR-T cells in haematological malignancies. Arch Immunol Ther Exp (Warsz) 68(6):34CrossRef

La Torre M et al (2013) Malnutrition and pancreatic surgery: prevalence and outcomes. J Surg Oncol 107(7):702–708CrossRef

10.

Lemos Pdos S, de Oliveira FL, Caran EM (2014) Nutritional status of children and adolescents at diagnosis of hematological and solid malignancies. Rev Bras Hematol Hemoter 36(6):420–3CrossRef

11.

von Meyenfeldt M (2005) Cancer-associated malnutrition: an introduction. Eur J Oncol Nurs 9(Suppl 2):S35–S38CrossRef

12.

Mondello P et al (2014) Emerging markers of cachexia predict survival in cancer patients. BMC Cancer 14:828CrossRef

13.

Fearon KC, Glass DJ, Guttridge DC (2012) Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 16(2):153–166CrossRef

14.

Xia LJ et al (2020) Significance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio and prognostic nutritional index for predicting clinical outcomes in T1–2 rectal cancer. BMC Cancer 20(1):208CrossRef

15.

Jager-Wittenaar H, Ottery FD (2017) Assessing nutritional status in cancer: role of the Patient-Generated Subjective Global Assessment. Curr Opin Clin Nutr Metab Care 20(5):322–329CrossRef

16.

Cessot A et al (2011) Defining the clinical condition of cancer patients: it is time to switch from performance status to nutritional status. Support Care Cancer 19(7):869–870CrossRef

17.

Co-Reyes E et al (2012) Malnutrition and obesity in pediatric oncology patients: causes, consequences, and interventions. Pediatr Blood Cancer 59(7):1160–1167CrossRef

18.

Lange BJ et al (2005) Mortality in overweight and underweight children with acute myeloid leukemia. JAMA 293(2):203–211CrossRef

19.

Suzuki H et al (2013) Cancer cachexia–pathophysiology and management. J Gastroenterol 48(5):574–594CrossRef

20.

Planas M et al (2016) Prevalence of hospital malnutrition in cancer patients: a sub-analysis of the PREDyCES(R) study. Support Care Cancer 24(1):429–435CrossRef

21.

Sanford DE et al (2014) Severe nutritional risk predicts decreased long-term survival in geriatric patients undergoing pancreaticoduodenectomy for benign disease. J Am Coll Surg 219(6):1149–1156CrossRef

22.

Saucillo DC et al (2014) Leptin metabolically licenses T cells for activation to link nutrition and immunity. J Immunol 192(1):136–144CrossRef

23.

Wensveen FM et al (2015) Interactions between adipose tissue and the immune system in health and malnutrition. Semin Immunol 27(5):322–333CrossRef

24.

Hu Y et al (2017) Potent anti-leukemia activities of chimeric antigen receptor–modified T cells against CD19 in Chinese patients with relapsed/refractory acute lymphocytic leukemia. Clin Cancer Res 23(13):3297–3306CrossRef

25.

Porter DL et al (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine 7(303):303ra139-303ra139CrossRef

26.

Porter DL et al (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725–733CrossRef

27.

McLean TW et al (2020) Hypoalbuminemia in children with cancer treated with chemotherapy. Pediatr Blood Cancer 67(2):e28065CrossRef

28.

Yilmaz M et al (2020) The effect of malnutrition on mortality in hospitalized patients with hematologic malignancy. Support Care Cancer 28(3):1441–1448CrossRef

29.

Tandon S et al (2015) Effect of pre-treatment nutritional status, folate and vitamin B12 levels on induction chemotherapy in children with acute lymphoblastic leukemia. Indian Pediatr 52(5):385–389CrossRef

30.

Marini A et al (1989) Serum cholesterol and triglycerides in hematological malignancies. Acta Haematol 81(2):75–79CrossRef

31.

Jiang Y et al (2020) Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy. Support Care Cancer 28(11):5569–5579CrossRef

32.

Idogun SE, Omoti CE (2011) Effects of chemotherapy on plasma lipids and lipoproteins in Nigerian patients with haematological malignancy. Niger Postgrad Med J 18(1):16–19PubMed

33.

Kuliszkiewicz-Janus M, Malecki R, Mohamed AS (2008) Lipid changes occuring in the course of hematological cancers. Cell Mol Biol Lett 13(3):465–474CrossRef

34.

Alwarawrah Y, Kiernan K, MacIver NJ (2018) Changes in nutritional status impact immune cell metabolism and function. Front Immunol 9:1055CrossRef

35.

Argiles JM, Busquets S, Lopez-Soriano FJ (2003) Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care 6(4):401–406PubMed

36.

Shimabukuro-Vornhagen A et al (2018) Cytokine release syndrome. J Immunother Cancer 6(1):56CrossRef

37.

Najera O et al (2004) Flow cytometry study of lymphocyte subsets in malnourished and well-nourished children with bacterial infections. Clin Diagn Lab Immunol 11(3):577–580PubMedPubMedCentral

38.

Elmoamly S, Afif A (2018) Can biomarkers of coagulation, platelet activation, and inflammation predict mortality in patients with hematological malignancies? Hematology 23(2):89–95CrossRef

39.

Kharfan-Dabaja MA et al (2018) Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score. Br J Haematol 180(6):854–862CrossRef

Titel: Nutritional status alterations after chimeric antigen receptor T cell therapy in patients with hematological malignancies: a retrospective study
verfasst von: Shuyi Ding
Lingxia Cai
Aiyun Jin
Xiaoyu Zhou
Jiali Yan
Linqin Wang
Houli Zhao
Tingting Wang
Yongxian Hu
Publikationsdatum: 05.01.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 4/2022
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-021-06639-2

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Nutritional status alterations after chimeric antigen receptor T cell therapy in patients with hematological malignancies: a retrospective study